| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MAP2K4 |
| Uniprot No | P45985 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 33-399aa |
| 氨基酸序列 | AVSSMQGKRKALKLNFANPPFKSTARFTLNPNPTGVQNPHIERLRTHSIE SSGKLKISPEQHWDFTAEDLKDLGEIGRGAYGSVNKMVHKPSGQIMAVKR IRSTVDEKEQKQLLMDLDVVMRSSDCPYIVQFYGALFREGDCWICMELMS TSFDKFYKYVYSVLDDVIPEEILGKITLATVKALNHLKENLKIIHRDIKP SNILLDRSGNIKLCDFGISGQLVDSIAKTRDAGCRPYMAPERIDPSASRQ GYDVRSDVWSLGITLYELATGRFPYPKWNSVFDQLTQVVKGDPPQLSNSE EREFSPSFINFVNLCLTKDESKRPKYKELLKHPFILMYEERAVEVACYVC KILDQMPATPSSPMYVD |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MAP2K4重组蛋白的参考文献示例(注：内容为模拟生成，非真实文献)：
1. **"Expression and Purification of Recombinant MAP2K4 in Escherichia coli"**
- 作者：Smith A, et al.
- 摘要：报道了在大肠杆菌中高效表达和纯化MAP2K4重组蛋白的方法，通过优化诱导条件和亲和层析技术获得高活性蛋白，用于体外激酶活性分析。
2. **"Structural Insights into MAP2K4 Kinase Domain by X-ray Crystallography"**
- 作者：Zhang L, et al.
- 摘要：解析了MAP2K4激酶域的晶体结构，揭示了其与ATP结合口袋的构象特征，为靶向该蛋白的药物设计提供了结构基础。
3. **"Functional Characterization of MAP2K4 in JNK Signaling Pathway"**
- 作者：Jones R, et al.
- 摘要：利用重组MAP2K4蛋白验证其在JNK通路中的调控作用，发现其磷酸化活性受上游激酶MAP3K1的调控，并影响细胞凋亡过程。
4. **"MAP2K4 Recombinant Protein as a Therapeutic Target in Pancreatic Cancer Models"**
- 作者：Wang H, et al.
- 摘要：通过体外实验证明，抑制重组MAP2K4蛋白的活性可阻断肿瘤细胞的侵袭和迁移，提示其在胰腺癌治疗中的潜在应用价值。
(提示：实际文献需通过PubMed、Web of Science等数据库检索确认。)
**Background of MAP2K4 Recombinant Protein**
Mitogen-activated protein kinase kinase 4 (MAP2K4), also known as JNK-activating kinase 1 (JNKK1) or MKK4. is a dual-specificity serine/threonine kinase within the MAPK signaling cascade. It functions as a critical mediator in cellular responses to stress, cytokines, and growth signals by phosphorylating and activating downstream c-Jun N-terminal kinase (JNK) and p38 MAPK pathways. These pathways regulate diverse processes, including apoptosis, differentiation, inflammation, and proliferation.
Recombinant MAP2K4 protein is engineered in vitro using expression systems (e.g., *E. coli*, mammalian cells) to produce a purified, biologically active form of the kinase. This recombinant tool retains the enzymatic activity required for studying MAP2K4’s role in signaling networks. Structurally, it often includes conserved catalytic domains and regulatory regions, sometimes fused with tags (e.g., GST, His-tag) to facilitate purification and detection.
Research applications of MAP2K4 recombinant protein span *in vitro* kinase assays, signal transduction studies, and drug discovery. It aids in elucidating mechanisms underlying diseases linked to MAP2K4 dysregulation, such as cancer, neurodegenerative disorders, and autoimmune conditions. For example, MAP2K4 mutations or altered expression are observed in breast, ovarian, and pancreatic cancers, suggesting its dual role as a tumor suppressor or promoter depending on context.
Additionally, the recombinant protein serves as a substrate or activator in high-throughput screens to identify inhibitors or modulators targeting the JNK/p38 pathways, offering therapeutic potential. Its use in cellular models further clarifies how MAP2K4 interacts with upstream regulators (e.g., MAP3Ks) and downstream effectors, refining our understanding of stress-response pathways and their crosstalk with other signaling networks.
In summary, MAP2K4 recombinant protein is a vital tool for dissecting MAPK-related biology and developing targeted therapies for diseases driven by pathway aberrations.
×
